Zymeworks Quarterly Income Statement
NASDAQ: ZYMEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zymeworks revenue and earnings
In the quarter ended Jun 30, 2026, Zymeworks generated $4.6 million in revenue, down 90.6% from the same quarter a year earlier. Zymeworks reported a net loss of $45.0 million, compared with net income of $2.3 million a year earlier. Operating margin was -919.0%.
Diluted earnings per share came in at -$0.62, down from $0.03.
Summary generated from market data by MetaCap's automated system. Methodology
Zymeworks income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.59M | 2.41M | 2.52M | 27.61M | 48.73M | 27.11M | 31.03M | 16.00M | 19.24M | 10.03M | 16.93M | 16.51M |
| Revenue growth (YoY) | -90.58% | -91.12% | -91.90% | +72.59% | +153.21% | +170.29% | +83.33% | -3.07% | +174.82% | -71.81% | -95.79% | +527.37% |
| Research & Development | 27.43M | 34.46M | 31.23M | 35.58M | 34.45M | 35.74M | 37.06M | 36.35M | 29.16M | 32.04M | 25.52M | 32.77M |
| Operating Income | -42.18M | -47.12M | -44.15M | -22.11M | -674.00K | -25.61M | -22.22M | -34.20M | -42.89M | -37.80M | -23.42M | -33.24M |
| Other Income (Expense) | 196.00K | 120.00K | -302.00K | 315.00K | -621.00K | 49.00K | 344.00K | -204.00K | 114.00K | 304.00K | -832.00K | 634.00K |
| Pretax Income | -45.29M | -46.35M | -41.48M | -18.27M | 2.13M | -22.14M | -17.79M | -29.62M | -37.62M | -31.58M | -19.20M | -27.58M |
| Income Tax | -273.00K | -2.19M | -270.00K | 1.34M | -186.00K | 496.00K | 5.71M | 226.00K | 68.00K | 75.00K | -4.72M | 1.11M |
| Net Income | -45.02M | -44.16M | -41.21M | -19.60M | 2.32M | -22.64M | -23.51M | -29.85M | -37.69M | -31.65M | -14.48M | -28.69M |
| Net Income growth (YoY) | -2042.99% | — | — | — | — | — | — | — | — | — | -104.68% | — |
| EPS (Basic) | -0.62 | -0.59 | -0.55 | -0.26 | 0.03 | -0.30 | -0.32 | -0.39 | -0.49 | -0.42 | -0.19 | -0.41 |
| EPS (Diluted) | -0.62 | -0.59 | -0.55 | -0.26 | 0.03 | -0.30 | -0.32 | -0.39 | -0.49 | -0.42 | -0.18 | -0.41 |
| Shares Outstanding (Basic) | 72.99M | 74.67M | — | 75.77M | 75.34M | 75.17M | — | 76.13M | 76.39M | 76.21M | — | 70.58M |
| Shares Outstanding (Diluted) | 72.99M | 74.69M | — | 75.78M | 77.38M | 75.23M | — | 76.16M | 76.40M | 76.25M | — | 70.58M |
| EBITDA | -41.22M | -46.16M | -43.25M | -21.20M | 211.00K | -24.63M | -21.22M | -33.17M | -41.79M | -36.74M | -21.89M | -30.84M |
| Operating Margin | -918.95% | -1956.73% | -1755.55% | -80.07% | -138.00% | -94.48% | -71.60% | -213.78% | -222.87% | -376.89% | -138.37% | -201.36% |
| Net Margin | -980.81% | -1833.97% | -1638.53% | -70.99% | 4.76% | -83.50% | -75.75% | -186.56% | -195.84% | -315.58% | -85.56% | -173.80% |
This table shows 12 quarterly periods of Zymeworks's income statement, from Q2 2026 back to Q3 2023, across 14 line items including revenue, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow ZYME's reporting calendar. What is a income statement?